| Name | Title | Contact Details |
|---|
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.
Marwan M. Shaykh, M.D. is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mr. Gallagher is Senior Vice President & Chief Financial Officer at RRD International, LLC. Mr. Gallagher provides strategic, operational, and financial leadership to RRD. His primary responsibilities are planning, implementing, managing, and controlling all financial-related activities including the development of financial and operational strategies. Mr. Gallagher has over 20 years of finance experience in the biopharma industry with both multi-national corporations and commercial-stage public biotechnology companies. He has an extensive background in all areas of corporate controllership, including financial planning & analysis, cost control, management accounting, corporate administration, and systems implementation. He has supported all aspects of product development and commercialization, including the negotiation and execution of licensing and collaboration agreements with major pharma partners. Mr. Gallagher served previously as Vice President of Finance for Optimer Pharmaceuticals and, prior to that, as Senior Director of Finance and Corporate Controller for Adolor Corporation. He had a central role in the sale of both companies. Mr. Gallagher spent the first 10 years of his career with Therakos, Inc. (a Johnson & Johnson company) and Merck & Co., Inc. He received his BS in Finance from The Pennsylvania State University and is an active Certified Management Accountant (CMA).
USLAB is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.